AU615711B2 – (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active ingredient
– Google Patents
AU615711B2 – (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active ingredient
– Google Patents
(cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active ingredient
Download PDF
Info
Publication number
AU615711B2
AU615711B2
AU28670/89A
AU2867089A
AU615711B2
AU 615711 B2
AU615711 B2
AU 615711B2
AU 28670/89 A
AU28670/89 A
AU 28670/89A
AU 2867089 A
AU2867089 A
AU 2867089A
AU 615711 B2
AU615711 B2
AU 615711B2
Authority
AU
Australia
Prior art keywords
methylenebis
phosphonic acid
lower alkyl
compound
cycloalkylamino
Prior art date
1988-01-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28670/89A
Other versions
AU2867089A
(en
Inventor
Tetsushi Abe
Yasuo Isomura
Shuichi Sakamoto
Makoto Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-01-20
Filing date
1989-01-20
Publication date
1991-10-10
1989-01-20
Application filed by Yamanouchi Pharmaceutical Co Ltd
filed
Critical
Yamanouchi Pharmaceutical Co Ltd
1989-07-20
Publication of AU2867089A
publication
Critical
patent/AU2867089A/en
1991-10-10
Application granted
granted
Critical
1991-10-10
Publication of AU615711B2
publication
Critical
patent/AU615711B2/en
2009-01-20
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/66—Phosphorus compounds
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
C07F9/02—Phosphorus compounds
C07F9/28—Phosphorus compounds with one or more P—C bonds
C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
C07F9/3839—Polyphosphonic acids
C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N…..H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N…..O, N…..S, N…..C(=X)- (X =O, S), N…..N, N…C(=X)…N (X =O, S)
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P19/00—Drugs for skeletal disorders
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
C07F9/02—Phosphorus compounds
C07F9/28—Phosphorus compounds with one or more P—C bonds
C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
C07F9/40—Esters thereof
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
C07F9/02—Phosphorus compounds
C07F9/28—Phosphorus compounds with one or more P—C bonds
C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
C07F9/40—Esters thereof
C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
C07F9/4025—Esters of poly(thio)phosphonic acids
C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N…..H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N…..O, N…..S, N…..C(=X)- (X =O, S), N…..N, N…C(=X)…N (X =O, S)
Abstract
(Cycloalkylamino)methylenebisphosphonic acids and esters (I) and salts thereof
Description
A 4
AUSTRALIA
PATENTS ACT 1952 615711 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority: Related Art: o000o0 0 0 0 I TO BE COMPLETED BY APPLICANT 0 0o o ,Name of Applicant: o o* 00 0 0 0 0 SAddress of Applicant: 4 Actual Inventor: e p a 0 9 O0 Address for Service? a 0 0 YAMANOUCHI PHARMACEUTICAL CO.,
LTD.
3-11, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo, Japan 1. YASUO ISOMURA 2. MAKOTO TAKEUCHI 3. SHUICHI SAKAMOTO 4. TETSUSHI ABE ARTHUR S. CAVE CO.
Patent Trade Mark Attorneys Level Barrack Street SYDNEY N.S.W. 2000
AUSTRALIA
o0 0 «.iomplete Specification for the invention (CYCLOALKYLAMINO)METHYLENEBIS(PHOSPHONIC ACID) AND CONTAINING THE SAME AS AN ACTIVE INGREDIENT.
entitled MEDICINEc The following statement is a full description of this invention including the best method of performing it known to me:- 1 ASC 49
I
To: Yampnouchi Pharmaceutical Co., Ltd.
The Commissioner of Patents 4 Presidnt; Shigeo Morioka ARTHUR S. CAVE CO.
PATENT AND TRADE MARK ATTORNEYS SY YON:
B
:ti: i, Signature of Declarant(s) Ilryr; __W4 .4.
SPECIFICATION
Title of the Invention (Cycloalkylamino)methylenebis(pospshonic acid) and medicines containing the same as an active ingredient Background of the Invention Field of the Invention The present invention relates to (cycloalkylamino)methylenebis(phosphonic acid), lower alkyl ester thereof or pharmaceutically acceptable salts thereof which are useful as medicines having a bone resorption inhibitory effect as well as an anti-inflammatory effect and an antirheumatic effect and also relates to medicines containing the compounds as an active ingredient.
oo0 So oo 000 o oa O 0 oC 0 ,0 <3 e P 0 t 0' 0 tQ Description of the related art o Some derivatives of (cycloalkylamino)methylenebis(phosphonic acid) are known. Japanese patent laid-open No. 37,829/79 discloses compounds having an unsubstituted cyclopentyl group or a cyclohexyl group and Japanese patent publication No. 12,319/80 discloses a compound having a cyclcbexyl group as the cycloalkyl group respectively. These Japanese patent gazettes mention that these compounds can be used as agricultural chemicals, especially as herbicide and that they can be use in a method for preventing precipitation in water or in aqueous solution, but are quite silent on the usability of the compounds as medicines.
lh- _1
.J
An object of the present invention is to provide (cycloalkylamino)methylenebis(phosphonic acid) derivatives having unsubstituted or substituted cycloalkyl group having 3 to 10 carbon atoms and are useful for a bone-resorption inhibitor and an anti-arthritis.
Summary of the Invention The present invention provides a pharmaceutical composition containing, as an active ingredient, (cycloalkylamino)methylenebis(phosphonic acid) represented by the general formula: 1
OR
SOR 4 (CI-2) NHCHF
OR
3 S: R *in which, R, R 1
R
2
R
3 and R 4 represent a hydrogen atom or a lower alkyl group, and n represents an integer from 3 to a lower alkyl ester thereof; or a pharmaceutically acceptable salt thereof.
The present invention provides also a bone-resorption inhibitor and an anti-arthritis containing, as an active ingredient, the compound S:j" represented by the general formula a lower alkyl ester thereof or a j 'pharmaceutically acceptable salt thereof.
The present invention provides also a novel compound or a lower alkyl ester thereof represented by the general formula (I) 1 2 3 4 in which R, R R R and R represent a hydrogen atom or a lower alkyl group, n represents an integer from 3 to f 3 ,vL* but R represents a lower alkylgroup when n is 5 or 6, or a pharmaceutically acceptable salt thereof.
The lower alkvl group in the general formula is a linear or branched hydrocarbon group having 1 to 5 carbon atoms. The typical lower alkyl group is methyl group, ethyl group, propyl group or isopropyl group.
The group represented by a chemical structure
(CHI
2 )n
R
in the general formula represents a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group or a cyclodecyl group each of which is substituted by a lower alkyl group or unsubstituted.
The salt of the compound is a salt with pharmaceutically acceptable base. As preferable salts, it can be mentioned salts with inorganic bases such as sodium salts, potassium salts or the like and salts "F with organic bases such as ammonium salts, triethylamine salts or the like.
on Preparation of the compounds 4 The compounds of the present invention can be prepared in accordance with the following reaction formula: -3ivS I' L 11_1 ~I~ O lower alkyl group
OR
1
(R
3
(CH
2 n NH2 HC O lower alkyl group HPO OR 2 0 lower alkyl group OR2(R)
R
(III)
(IV)
OR
OR 4 (CH-2)n NI-ICH 3
R
0o (I) 0 0 0 In this reaction, all components of a cycloalkylamine a lower alkyl ortho-formate (III) and a phosphorous acid or its lower alkyl ester S (IV) are mixed each in the corresponding reaction amount and are heated, A reaction solvent is not specifically required. The reaction is performed oo generally at 100 to 200 OC, preferable at 150 °C or so, for 10 to 0 minutes.
o; For isolating and purifying the thus obtained reaction product, for example, the reaction mixture is charged on a silica gel column and eluted with a mixed solvent of methanol-chloroform. In the above mentioned reaction, the corresponding bisphosphonic acid or bisphosphonate can be obtained respectively from the phosphorous acid or its ester (IV).
The bisphosphonates can be converted into the corresponding bisphosphonic acids by hydrolysis. The hydrolysis is generally carried out by heating the bisphosphonates under reflux in a concentrated -4
V'I
L I hydrochloric acid. Alternatively, the bisphosphonates can be treated with a strong acid or a trimethylsilyl halide in a water-free solvent. For the method, in general, a commercial anhydrous hydrobromic acid in acetic acid can be used directly or in a form of a pertinently diluted solution, or a solution of a trimethylsilyl iodide as dissolved in a solvent such as carbon tetrachloride, dimethylformamide, chloroform, toluene, etc. can be used.
Regarding the temperature, the hydrolysis is carried out with cooling or heating. For example, when the ester is hydrolyzed with a trimethylsilyl halide with cooling at -10 °C or lower, a partially hydrolyzed product is obtained.
When the bisphosphonic acid is to be converted into its salt, the acid is treated with a base such as sodium hydroxide, potassium hydroxide, o ammonia or organic amines, etc. in a conventional manner.
Pharmaceutical use The compounds and their salts provided by the present invention have a bone resorption-inhibitory action and also have an action for inhibiting hypercalcemia caused by bone resorption. In addition, these are recognized to have excellent anti-inflammatory action and antipyretic and analgesic action.
0 P" Experimental test methods and results are mentioned hereunder so as to support the inhibitory effect on hypercalcemia of the compounds (I) and their salts provided by the present invention.
-i I- -I--l~-~-'Ye~uuauillrcrm~u Inhibitory Effect on Hypercalcemia of Rats Rats of hypercalcemia induced by administration of parathyroid hormone were used, and the decrement of the serum calcium amount by administration of the compound was measured.
Test Method jg/kg of human 1-34 parathyroid hormone, (PTH, manufactured by Peptide Laboratory) which was dissolved in a 0.1 BSA (bovine serum albumin)-containing physiological saline (the contents of the PTH is 6 ig/ml) was intravenously injected in an amount of 7,t 30 I-g/kg (5 nl/kg as the solution) to 5-week male Wistar rats which had 0o 0 ,a been fasting for 20 hours. Only 0.1 BSA-containing physiological o saline was injected to the normal control group in the same manner. ,o0 J minutes after the PTH injection, the rats were etherized and then subjected to celiotomy, whereby the blood was collected from the abdominal cava with a vacuum blood-collecting tube. The blood collected was immediately centrifuged by 3000 rpm, at 4 °C for 10 minutes to isolate the serum. The ionized calcium concentration in the serum was immediately measured with a Ca++ meter (Sera 250, manufactured by Horiba Manufacturing Co.).
The compounds of the present invention were dissolved using sodium hydroxide and hydrochloric acid, in physiological saline (pH 7.4), for subcutaneous administration, in such amounts that the dose amounted to 2 ml/kg. They were administered 72 hours before the PTH injection.
A physiological saline or a distilled water was administered to the normal control group and the control group, in the same manner, As a reference -6 I I ift compound, salmon calcitonin (SCT, manufactured by Armour Co.) was used for the meL.urement. The SCT was subcutaneously administered at the dose of 2 ml/kg 30 minutes before the PTH injection.
The results for each group were expressed in terms of mean S. E. (standard error) and comparison was made among the groups by testing by one-way analysis of variance. The significance level was taken at 5 Results The results obtained by the subcutaneous administration are shown in Table 1.
C, 00 ooo 0 0 Co o C' Table 1 Subcutaneous administration Compound Tested Dose N Serum Ca (mg/kg) (m mole .2) Normal control -5 1.42 0.02 Control 5 1.48 0.03 Compound of Example 8 0.3 5 1.25 0,02** Compound of Example S 1.5 5 1.12 0,02** Normal Control -5 1.41 0.02** Control 5 1.46 0.02 Compound of Example 15 0.03 5 1.37 0.02** Compound of Example 15 0.1 5 1.20 0.02** o ,o fl -7iii 1 'j E~V Table 1 (continued) Compound Tested Dose N Serum Ca (mg/kg) (m mole R2 Normal control -5 1.34 0.02** Control -5 1L43 0.01 Compound of Examplel14 0.1 5 1.34 ±0.02** Compound of Examplel14 0.3 5 1.21 ±0.01* Compound of Example 5 0.1 5 1.12 ±0.01* Compound of Example 5 0.3 5 0.97 0.02** Normal. Control 5 1.36 0.01 Control 5 1.45± 0,02 Compound of Example 9 0.1 5 1.31 0.01* Compound of Example 9 0.3 5 i-19 ±0.01** Compound of Example 10 0.1 5 1.35 ±0,01* Compound of Example 10 0.3 5 1.22 0,01 Normal control 5 1 .35 0,02** Control 5 1.44 0,01 Compound of Example 11 1.0 5 1.35 0,02** Normal control 5 1.38 0.0l Control 5 1.48 0.02 Compound of Example 7 0.3 5 1 .40 0,02** Compound of Example 7 1.0 5 1.29g 0.01 Compound of Example 6 0.3 5 1.33 0,03** Compound of Example 6 1.0 5 1. 12 ±0,03** Normal control -5 1.38 0.01 Control -5 1.49 0.00 ScT 0.3 IU 5 1.07 0.02** Note: Mean value S. E, :P<0,05 11<0.0l -8 ,2_ 4 4 *4 *Sea
S.
a 04 4 4.
a PTH-Induced Hypercalcemia in Rats Methods PTH (human PTH 1-34, 30 tgg/kg) was intravenously injected to rats (Wistar, male, about 3-week-old). The blood was collected 45 min. after PTH injection. Ionized calcium in the serum was measured with a Ca++ meter.
Test compounds were subcutaneously or orally administered three days before PTH injection. Results are expressed as mean E.
Statistical significance of the values was analyzed using One-Way ANOVA test p<0,05, p<0.01), Results PTH elevated serum Ca++ level probably by stimulation of calcium release from the bone. Bisphosphonates, the compound of Example (hereinafter, YM-21175-1) and APD*, were dose-dependently inhibited the increase of serum Ca++ level when they were subcutaneously or orally administered to the rats 3 day before PTH injection. YM-21175-1 was about 10 times more potent than APD in both cases of subcutaneous or oral administration, S* 4 r .9 .i Table 2.
Effects of YM-21 175-1 and APD on PTL--induced hypercalcemnia in rats 0 0 is, Dose N Serumn Ca (mng/kg) (m mole! 2) normal -5 1.42 0.02 control 5 1.49 0.02 A P D 0.03 sc 5 1.49 ±0.02 0.1 se 5 1.46 ±0.01 0.3 sc 5 1.41 ±0.02* A P) D 30 po 5 1.50 ±0.02 100 p0 5 1.42± 0,02 300 p0 5 1 .22 0.,02** YM 21175-1 0.01 sc 5 1.44 ±0.02 0.03 s c 5 1.36± 0,02** 0.1 sc 5 1. 15 ±0.01* normal (-PTII) 5 1-.35 0.02 control (+PTII1) -5 1.45 0.02 YM-21175-1 10 po 5 1.37 ±0.02 30 po 5 1.23 ±0.05"* 100 p0 5 1.05 004** APD (Ciba-Geigy); IJ2NCH2CII2C(P0311 2)2 Ir~ (a medicine for treating bone Paget available, on market) 10 1_1_1 YWX-..-.II Disuse Atrophy of Bone Induced by Neurectomy in Rats Methods Rats (Wistar, male, 6-week-old) were neurectomized at brachial plexisus so that their left forelimbs were disused. Two weeks later, left humerus was removed. The soft tissue around the bone was cleaned off and the bone was dehydrated and defatted with alcohol and acetone successively. Dry weight of the bones was measured.
Compounds were orally administered once a day for 2 weeks.
Results were expressed as mean iS. E. Statistical significance of the values was analyzed using One-Way ANOVA test p<0.05, p<0.01).
S" Results The dry weight of the denerved humerus was significantly decreased as compared with that of the sham-operated one. Oral administration of bisphosphonates, YM-21175-1 and APD, exhibited the dose-dependent inhibition of dry weight loss in the denerved humerus.
YM-21.175-1 was about 30 times superior to APD.
i -11 i..
.i i -Y-0-m -Po A Table 3.
Effects of YM-21175-1 and APD on disuse atrophy of bone induced by neurectomy in rats Dose N dry wt (mg/kg) (mg) sham-operated 6 154 3** control 6 113 2 A P D 10 5 126±3 5 128 ±4* 100 6 135 2** YM-21175-1 0.3 6 126 ±2 1 6 132 6** 3 6 135 6 150±4** a i .1 t fi
I,
Adjuvant-Induced Arthritis in Rats Methods A suspension of dead bacilli in oil was intradermally injected into left hind paws of rats (Lewis, male, 5-week-old). Compounds were orally given daily for 5 weeks, starting from the day of injection of the adjuvant.
Thickness of the left hind foot was measured and left femur was removed at the next day of last dosing. The bones were dehydrated and defatted, and then dry weight of them was measured. They were measured again after they were ashed, Bone mineral content (BMC) was calculated as ash wt/dry wt.
Results were expressed an mean E. Statistical significance of the values was analyzed using One-Way ANOVA test p<0.01).
12 -r i- Results Adjuvant-induced arthritis is one of popularly used models for rheumatoid arthritis in human. Arthritic rats induced by injection of the adjuvant show not only the swelling of the foot but also decrease of BMC, which is supporsed to be caused by increase of bone resorption and/or disuse of hindlimbs.
Indomethacin i mg/kg markedly inhibited the swelling of hindlimbs. It also inhibited the decrease of BMC as a result of the inhibition of development the arthritis. YM-21175-1 inhibited the swelling only at high doses but decrease of BMC at 1 mg/kg. Therefore there is probable to be difference of the inhibitory action between indomethacin and YM-21175-1. YM-21175-1 was more effective than
APD.
0 4 4 4, 4i 4 ~1 4 4o 4 n6 -13 i: r I i s i '1 Table 4.
Effects of YM-21175-1 and APD on adjuvant-induced arthritis in rats dose N thickness ash wt/dry wt (mg/kg) (mm) normal 6 6.4 0.0 54.8 0.1** control 6 13.5 0.1 49.5 0.4 indomethacin 1 6 7.6 52.3 0.2** A P D 1 6 12.1 ±0.6 50.4 ±0.3 io 3 6 11.6 0.7 51.2 0.4** 6 10.8 52.1 30 6 12.1 0.3 53.3 0.3** 100 6 9.3 56.6 0.3** r o o YM-21175-1 0.3 6 12.3 0.6 50.7 0.6 1 6 11.7 0.1 52.1 0.8** 3 6 12.3 0.8 53.1 0.4** .C 10 6 10.5 55.9 0.3** 30 5 9.5 57.6 0.3** The inhibitory effect of YM-21175-1 on bone loss was compared 2-E, with APD. As results in three kinds of experiments, YM-21175-1 is S: thought to be useful in the treatment of osteoporosis, rhumatoid arthritis and other diseases in which the bone resorption was accelerated, and besides YM-21175-1 is concluded to be more potent than APD.
From the test .esults, the compounds of the present invention were demonstrated to have an excellent action for reducing the amount of serum calcium. Accordingly, it is confirmed that the compounds of the 14 II I ,4 present invention have a bone-resorption inhibitory action. As diseases considered to be caused by an excessive bone-resorption, there may be mentioned Paget's disease, hypercalcemia, metastatic osteocarcinoma, and osteopsathrosis. Further, sthenic bone resorption to follow inflammatory arthritides such as chronic rheumatoid arthritis is an important problem from a clinical point of view. The compounds provided by the present invention can be used as remedial medicines for these diseases to inhibit the bone resorption and prevent the reduction of the bone amount or prevent the rising of the serum calcium value caused by the sthenic bone resorption or lower the value.
The compounds of the present invention and their salts can be S blended with any optional pharmaceutically acceptable carrier, vehicle, o attenuant, etc. to be formed into medical composition, such as tablets, o capsules, powder, granules, pills, etc. for oral administration of injection, syrup, suppositories, ointment, etc. for non-oral administration. The Sg amount of the dose of the compounds of the present invention is, o although varying in accordance with the administration route, patient's symptom, etc., generally from 1 mg/day/adult to 1 g/day/adult for oral administration, and from 0.1 to 10 mg/day/adult for non-oral administration.
)o Prescription ExampIle Examples for prescription of the compound of the present invention as a drug will be mentioned below.
Tablet: Compound of Example 8 5 mg 0164s:AB Lactose 119 mg Corn Starch 67 mg Calcium Carboxymethyl Cellulose 4 mg Magnesium Stearate 1 mg Total 200 mg g of the compound of Example 8, 119 g of lactose and 67 g of corn starch were uniformly blended, 40 ml of an aqueous 10 (w/w) hydroxypropyl cellulose solution was added thereto, and the resulting o o mixture was wet-granulated. The granules thus obtained were blended with 4 g of calcium carboxymethyl cellulose and 1 g of magnesium UV stearate, and the resulting mixture is formed into tablets each having a weight of 200 mg/tablet, Capsule: Compound of Example 8 5 mg Crystalline Cellulose 50 mg SCrystalline lactose 144 mg Magnesium Stearate 1 mg Total 200 nmg The above-mentioned ingredients were blended each in an amount of 1000 times of the above-mentioned amount and encapsulated in gelatin capsules each containing 200 mg of the mixture per one capsule,
I
-16 L1- T.i ilill- o-llI~~ Preparation Examples The process for manufacturing the compounds of the present invention will be explained in the following examples.
Example 1 OE t NHCH OE t OE t
PO
OE t A mixture of 4.0 g of cycloheptylamine, 6.27 g of ethyl orthoono formate and 19.5 g of diethylphosphite was heated at 150 OC with stirring for 1.5 hours. After cooling, the reaction solution was concentrated under reduced pressure to eliminate ethyl ortho-formate and diethylphosphite which were not reacted. Then, the residue was purified on silica gel column chromatography (methanol/chloroform 1/49) to give 9.0 g of tetraethyl (cycloheptylamino)methylenebis(phosphonate) as a pale yellow 0 °0 oil.
The physico-chemical characteristics of this product are as follows: Mass Spectrum (FAB Mass) 400 1) (ii) Nuclear Magnetic Resonance Spectrum (6 value, in CDC13) 1.32 (12H, OCH2CH3 x 4) 1.20 2.08 (12H, H methylene in cycloheptyl group) 2.96 (1H, -N H i 3.36 (1H, -NHCI--) -17- .1 .ii._9 4.00, 4.40 (814, -OcLJ2CH3 x 4) In the same manner as Example 1, the following compounds were prepared.
Example2 NHCH< OE
